Home › Pulmonary Sarcoidosis › NCT05567133
Risk Indicators of Sarcoidosis Evolution-Unified Protocol
RecruitingObservational study
Development of Clinical Prediction Models for Pulmonary Outcomes in Sarcoidosis
Who can join
Ages 19 and older · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Adults with a diagnosis of sarcoidosis over the age of 18 2. Case definition: we will follow the 1999 statement on sarcoidosis published by the American Thoracic Society for diagnosis which includes tissue biopsy confirmation and exclusion of alternative diagnoses including beryllium sensitization/chronic beryllium disease, mycobacterial, viral, and/or fungal infection Exclusion Criteria: 1. Inability to tolerate study procedures as determined by the investigator 2. Pregnant or breastfeeding 3. Concurrent medical diagnoses that would influence the expression of biomarkers will be considered an exclusion criterion. This includes diseases such as common variable immunodeficiency, HIV infection, or autoimmune diseases 4. Concurrent interstitial lung diseases such as hypersensitivity pneumonitis or idiopathic pulmonary fibrosis 5. Hematocrit (Packed Cell Volume) \< 25%
About the study
The purpose of this study is to develop prediction models that can prognosticate patients with sarcoidosis using clinical data and blood markers that can be obtained during a clinic visit.
Sponsor: University of California, San Francisco · Participants: 200 · Started: Jan 10, 2023
Contact the study team
- Laura Koth · Phone: 4155144369
Official record on ClinicalTrials.gov — NCT05567133
Locations in the U.S.
| Maryland | University of Maryland, Baltimore |
| Texas | UT Southwestern, Dallas |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.